All-trans Retinoic Acid Potentiates the Ability of Interferon Beta-1b to Augment Suppressor Cell Function in Multiple Sclerosis
Open Access
- 1 March 1998
- journal article
- clinical trial
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 55 (3) , 315-321
- https://doi.org/10.1001/archneur.55.3.315
Abstract
INTERFERON BETA-1B (Betaseron, Berlex Laboratories Inc, Richmond, Calif) and interferon beta-1a (Avonex, Biogen Inc, Cambridge, Mass) are widely used to treat ambulatory patients with multiple sclerosis (MS). Both preparations reduce MS attack frequency and disease activity as measured by serial magnetic resonance image scanning.1-4 Use of interferon beta-1b reduces accumulating disease burden as well. Benefit lasts more than 5 years for interferon beta-1b.5 Interferon beta preparations are only partly effective; almost all patients treated with these preparations relapse eventually. Perhaps efficacy could be improved if interferon beta were combined with another drug.Keywords
This publication has 1 reference indexed in Scilit: